Rob Wright shares experiences from day two of recent press tour of the Netherlands’ biopharmaceutical industry.
Rob Wright shares what makes the CNS Summit the best conference he has ever attended.
What sets the Netherlands biopharma sector apart from the rest of the world? That’s what Chief Editor Rob Wright hoped to find out as he began his press tour of the country’s biopharma industry.
Rob Wright discusses China’s history of intellectual property (IP) theft, and wonders if the government-sponsored 10-year initiative, Made in China 2025 (MIC 2025), could exacerbate the problem.
Rob Wright shares what he looks forward to learning about during an upcoming press tour of the Netherlands, beyond the fact that the European Medicines Agency (EMA) will be relocating there in 2019.
Mylan’s inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking accountability.
A question about GMOs submitted to our editorial board leads us to look more closely into this issue and how it affects the pharma industry.
Amir Kalali, M.D., former global head of Quintiles (now IQVIA) neuroscience center of excellence, provides insight on why he decided to found an educational conference, The CNS Summit, while still working as a biopharmaceutical industry executive.
What current biopharma leaders have the potential to “transcend” beyond this industry? Chief Editor Rob Wright gives his top three choices.
A primer on AI terminology for the upcoming August feature with Sanofi’s Medical Function EVP, Ameet Nathwani, M.D.
|
|
|
|
|
|
|
|
|